The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization (Q51061908)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2015

Language	Label	Description	Also known as
English	The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization	scientific article published in February 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

systemic therapy

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Christopher J. Weight

7

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

3

object named as

Cary P Gross

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

author name string

Simon P Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Holly Van Houten

4

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

R Houston Thompson

5

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Robert Abouassaly

6

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Stephen A Boorjian

8

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Bradley C Leibovich

9

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Nilay D Shah

10

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

language of work or name

0 references

publication date

1 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

85

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

2

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

442-450

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Axitinib for the Management of Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

EAU guidelines on renal cell carcinoma: the 2010 update

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

The role of metastasectomy in renal cell carcinoma in the era of targeted therapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

External validation of a claims-based algorithm for classifying kidney-cancer surgeries

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Comorbidity Measures for Use with Administrative Data

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2014.10.040

7 January 2021

Identifiers

10.1016/J.UROLOGY.2014.10.040

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 March 2018

http://europepmc.org/abstract/MED/25623717

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51061908&oldid=2266753600"